Clinical trial
GILT Docetaxel - Non-Small Cell Lung Cancer
NCT00174629 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00174629 |
|---|---|
| Title | GILT Docetaxel - Non-Small Cell Lung Cancer |
| Official title | Open-Label, Cooperative, Randomized, Multicenter Phase III Study on the Use of Cisplatin Resistant Genotype (ERCC1 Over-Expression) in Tumor RNA to Customize Chemotherapy in Stage IV-IIIB (Malignant Pleural Effusion) Non-Small-Cell Lung Cancer Patients |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Neoplasms |
| Intervention type | Drug |
| Interventions | Docetaxel/DDP, docetaxel/gemcitabine |
| Enrollment | 449 |
| Start date | Jun 1, 2001 |
| Primary completion | Jan 1, 2007 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 7, 2009 |
| Countries | Germany, Spain, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: